Get the Stockscreener App
90.08
0.64%
-0.37
Incyte Corp stock is traded at $90.08, with a volume of 118.92K.
It is down -0.64% in the last 24 hours and down -11.06% over the past month.
Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.
See More
Previous Close:
$90.45
Open:
$89.63
24h Volume:
118.92K
Relative Volume:
0.06
Market Cap:
$17.91B
Revenue:
$5.14B
Net Income/Loss:
$1.29B
P/E Ratio:
14.07
EPS:
6.4034
Net Cash Flow:
$1.33B
1W Performance:
-4.62%
1M Performance:
-11.06%
6M Performance:
+6.78%
1Y Performance:
+43.15%
1-Day Range:
$89.25
$90.11
1-Week Range:
$89.25
$93.91
52-Week Range:
$53.56
$112.29
Incyte Corp Stock (INCY) Company Profile
Name
Incyte Corp
Sector
Industry
Phone
(302) 498-6700
Address
1801 AUGUSTINE CUT-OFF, WILMINGTON, DE
Compare INCY vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INCY
Incyte Corp
|
90.01 | 18.00B | 5.14B | 1.29B | 1.33B | 6.4034 |
VRTX
Vertex Pharmaceuticals Inc
|
447.02 | 114.63B | 12.07B | 3.95B | 3.19B | 15.33 |
REGN
Regeneron Pharmaceuticals Inc
|
733.04 | 77.87B | 14.34B | 4.50B | 3.77B | 41.56 |
ARGX
Argen X Se Adr
|
675.35 | 42.32B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
302.53 | 40.67B | 3.71B | 313.75M | 465.38M | 2.2571 |
ONC
Beone Medicines Ltd Adr
|
275.44 | 30.50B | 5.36B | 287.73M | 924.18M | 2.5229 |
Incyte Corp Stock (INCY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Mar-16-26 | Downgrade | Jefferies | Buy → Hold |
| Feb-05-26 | Initiated | H.C. Wainwright | Buy |
| Jan-20-26 | Downgrade | Wells Fargo | Overweight → Equal Weight |
| Dec-08-25 | Upgrade | Mizuho | Neutral → Outperform |
| Nov-03-25 | Upgrade | Guggenheim | Neutral → Buy |
| Oct-08-25 | Downgrade | Oppenheimer | Outperform → Perform |
| Aug-06-25 | Upgrade | Wells Fargo | Equal Weight → Overweight |
| Aug-01-25 | Initiated | Barclays | Overweight |
| Jun-16-25 | Upgrade | Stifel | Hold → Buy |
| Mar-18-25 | Downgrade | Guggenheim | Buy → Neutral |
| Mar-18-25 | Downgrade | William Blair | Outperform → Mkt Perform |
| Dec-17-24 | Initiated | UBS | Neutral |
| Oct-29-24 | Upgrade | BofA Securities | Neutral → Buy |
| Oct-01-24 | Initiated | Wolfe Research | Outperform |
| Sep-18-24 | Downgrade | Truist | Buy → Hold |
| Jul-02-24 | Downgrade | BMO Capital Markets | Market Perform → Underperform |
| May-23-24 | Initiated | Deutsche Bank | Hold |
| Apr-23-24 | Initiated | Cantor Fitzgerald | Neutral |
| Feb-23-24 | Initiated | Jefferies | Buy |
| Feb-14-24 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Dec-13-23 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Dec-04-23 | Upgrade | Guggenheim | Neutral → Buy |
| Nov-21-23 | Downgrade | Goldman | Buy → Neutral |
| Jul-25-23 | Initiated | Citigroup | Buy |
| May-04-23 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-10-23 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Mar-24-23 | Upgrade | SVB Securities | Underperform → Market Perform |
| Jan-31-23 | Initiated | Piper Sandler | Overweight |
| Aug-03-22 | Downgrade | Evercore ISI | Outperform → In-line |
| Aug-03-22 | Downgrade | Guggenheim | Buy → Neutral |
| Jul-28-22 | Initiated | Wells Fargo | Equal Weight |
| Feb-09-22 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jan-18-22 | Upgrade | RBC Capital Mkts | Sector Perform → Outperform |
| Nov-19-21 | Initiated | BMO Capital Markets | Market Perform |
| Jul-20-21 | Upgrade | The Benchmark Company | Hold → Buy |
| Feb-10-21 | Downgrade | SVB Leerink | Mkt Perform → Underperform |
| Jan-07-21 | Initiated | Truist | Buy |
| Jan-04-21 | Upgrade | Guggenheim | Neutral → Buy |
| Jun-16-20 | Initiated | The Benchmark Company | Hold |
| May-06-20 | Downgrade | JP Morgan | Overweight → Neutral |
| Apr-29-20 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-01-20 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-24-20 | Resumed | William Blair | Outperform |
| Mar-13-20 | Upgrade | BofA/Merrill | Neutral → Buy |
| Feb-04-20 | Resumed | BofA/Merrill | Neutral |
| Jan-03-20 | Reiterated | BMO Capital Markets | Market Perform |
| Jan-03-20 | Downgrade | Mizuho | Buy → Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Oct-03-19 | Initiated | Mizuho | Buy |
| Sep-12-19 | Initiated | BMO Capital Markets | Market Perform |
| Sep-05-19 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Sep-05-19 | Resumed | Morgan Stanley | Equal-Weight |
| Sep-05-19 | Upgrade | Oppenheimer | Perform → Outperform |
| May-21-19 | Initiated | Credit Suisse | Neutral |
| May-03-19 | Downgrade | Barclays | Overweight → Equal Weight |
| Apr-11-19 | Initiated | Stifel | Hold |
| Apr-03-19 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jan-24-19 | Upgrade | William Blair | Mkt Perform → Outperform |
View All
Incyte Corp Stock (INCY) Latest News
Nordea Investment Management AB Acquires 291,293 Shares of Incyte Corporation $INCY - MarketBeat
Chronic Hand Eczema Pipeline 2026: Key Companies, MOA, ROA, and Clinical Trials Evaluation by DelveInsight | Incyte Corp, LEO Pharma, Asana BioSciences, Arcutis Biotherapeutics, Innovaderm Research - Barchart
Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data at the 2026 American Academy of Dermatology (AAD) Annual Meeting - BioSpace
Swiss Life Asset Management Ltd Increases Stake in Incyte Corporation $INCY - MarketBeat
New England Research & Management Inc. Acquires New Stake in Incyte Corporation $INCY - MarketBeat
Incyte Corp. (INCY) reports Q4 2025 revenue growth of 28% to $1.51B driven by Jakafi and Opzelura sales - MSN
INCY wins EC approval for label expansion of oncology drug Zynyz - MSN
Analysts differ in opinion on Jakafi drug maker Incyte (INCY) - MSN
Incyte Corp. stock underperforms Friday when compared to competitors - MarketWatch
Incyte to Highlight Late-Breaking Hidradenitis Suppurativa Data a - The National Law Review
Is Incyte Stock Outperforming the Dow? - Barchart
INCY News | INCYTE CORP (NASDAQ:INCY) - ChartMill
Cutaneous Squamous Cell Carcinoma Pipeline Grows as 45+ Pharma - openPR.com
Cutaneous Squamous Cell Carcinoma Pipeline Grows as 45+ Pharma Companies Advance Novel Skin Cancer Therapies, Finds DelveInsight | Incyte, Shanghai Henlius Biotech, Novartis, Rakuten Medical, Roche, G - Barchart.com
Incyte (NASDAQ:INCY) Insider Sells 18,667 Shares - MarketBeat
Incyte president Pablo Cagnoni sells $1.76 million in stock - Investing.com
Incyte (NASDAQ: INCY) R&D head exercises options, sells 18,667 shares - Stock Titan
Incyte Corp Stock (ISIN: US45337C1027) Faces Pressure Amid Oncology Pipeline Setbacks and Market Vol - AD HOC NEWS
Incyte (INCY) Downgraded by Jefferies; Price Target Lowered | IN - GuruFocus
Incyte Corp. stock underperforms Wednesday when compared to competitors - MarketWatch
Faithward Advisors LLC Takes $4.45 Million Position in Incyte Corporation $INCY - MarketBeat
INCY Stock Price, Quote & Chart | INCYTE CORP (NASDAQ:INCY) - ChartMill
Incyte’s Latin American MINJUVI Steps Expand Oncology Story Beyond Jakafi - Yahoo Finance
Incyte (INCY) Strengthens Partnership with Knight for MINJUVI in Latin America - GuruFocus
Incyte Corp. stock outperforms competitors on strong trading day - MarketWatch
Form 144: INCY (NASDAQ: INCY) reports 18,667-share stock option sale - Stock Titan
INCY's phase III Monjuvi study meets key goals in first-line lymphoma - MSN
Incyte: Valued Like A Single-Drug Company Despite Diversifying Revenue (NASDAQ:INCY) - Seeking Alpha
How Diverging Zynyz Outcomes In Cancer Trials At Incyte (INCY) Have Changed Its Investment Story - simplywall.st
Jefferies downgrades Incyte stock rating on patent cliff concerns - Investing.com
Incyte Drug Zynyz Approved in Europe for Anal Canal Cancer Treatment - MyChesCo
How Investors Are Reacting To Incyte (INCY) Winning EU Approval For Zynyz In Advanced Anal Cancer - Yahoo Finance
Incyte Corporation (NASDAQ:INCY) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
INCYIncyte Corp Stock Price and Quote - Finviz
European Commission Approves J&J Prostate Drug, PLX Fabry Dosing, Incyte's Zynyz Second Indication - RTTNews
Mackenzie Financial Corp Has $38.43 Million Stock Holdings in Incyte Corporation $INCY - MarketBeat
INCY Technical Analysis | Trend, Signals & Chart Patterns | INCYTE CORP (NASDAQ:INCY) - ChartMill
Incyte Corp. stock underperforms Thursday when compared to competitors - MarketWatch
Incyte (INCY) Down 4.2% Since Last Earnings Report: Can It Rebound? - Yahoo Finance
Incyte Sets December Investor Lineup as Pipeline Progress Draws Market Attention - MSN
Incyte (INCY): Buy, Sell, or Hold Post Q4 Earnings? - Yahoo Finance
Incyte Advances New Early Stage Drug INCA033989 Into Human Testing - TipRanks
Incyte at Barclays Conference: Navigating Post-Jakafi Future - Investing.com
Russell Investments Group Ltd. Has $68.44 Million Stock Position in Incyte Corporation $INCY - MarketBeat
Korea Investment CORP Raises Stock Position in Incyte Corporation $INCY - MarketBeat
Incyte Corp. stock underperforms Tuesday when compared to competitors - MarketWatch
Incyte at Leerink Global Healthcare Conference: Strategic Growth Focus - Investing.com
Incyte Corporation $INCY Shares Purchased by Vestcor Inc - MarketBeat
INCY Wins EC Approval for Label Expansion of Oncology Drug Zynyz - Finviz
Incyte becomes third company to receive CRL over issues at Novo Indiana factory - Endpoints News
Stifel reiterates Incyte stock rating after FDA setback - Investing.com
Incyte Corp Stock (INCY) Financials Data
Revenue
Net Income
Cash Flow
EPS
2.79%
0.30%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):